167 related articles for article (PubMed ID: 24167025)
1. Expression of p53 in imprint smears of endometrial carcinoma.
Kosmas K; Stamoulas M; Marouga A; Kavantzas N; Patsouris E; Athanassiadou P
Diagn Cytopathol; 2014 May; 42(5):416-22. PubMed ID: 24167025
[TBL] [Abstract][Full Text] [Related]
2. p53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy.
Bonfitto VL; de Angelo Andrade LA
Sao Paulo Med J; 2003 Jul; 121(4):163-6. PubMed ID: 14595509
[TBL] [Abstract][Full Text] [Related]
3. p53 overexpression as a prognostic indicator in endometrial carcinoma.
Ozalp S; Yalcin OT; Tanir HM; Kabukcuoglu S; Erol G
Eur J Gynaecol Oncol; 2003; 24(3-4):275-8. PubMed ID: 12807239
[TBL] [Abstract][Full Text] [Related]
4. [A study on expression of tumor suppressor gene p53 in endometrial carcinoma].
Xue F; Jiao S; Zhao F
Zhonghua Fu Chan Ke Za Zhi; 1995 Nov; 30(11):647-50. PubMed ID: 8745486
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma.
Iwai K; Fukuda K; Hachisuga T; Mori M; Uchiyama M; Iwasaka T; Sugimori H
Gynecol Oncol; 1999 Mar; 72(3):351-9. PubMed ID: 10053107
[TBL] [Abstract][Full Text] [Related]
6. Preoperative cervical cytology in endometrial carcinoma and its clinicopathologic relevance.
Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H; Yamasaki F
Gynecol Oncol; 1999 Mar; 72(3):273-7. PubMed ID: 10053095
[TBL] [Abstract][Full Text] [Related]
7. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
8. Pathological findings in early-stage endometrial cancer.
Zehavi S; Schneider D; Bukovsky I; Halperin R
Eur J Gynaecol Oncol; 2003; 24(1):18-20. PubMed ID: 12691310
[TBL] [Abstract][Full Text] [Related]
9. Expression of nm23 in normal, hyperplastic and neoplastic endometrial tissues.
Brustmann H; Naudé S
Pathol Res Pract; 1999; 195(12):829-34. PubMed ID: 10631718
[TBL] [Abstract][Full Text] [Related]
10. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
[TBL] [Abstract][Full Text] [Related]
11. Computerized image analysis of p53 and proliferating cell nuclear antigen expression in benign, hyperplastic, and malignant endometrium.
Elhafey AS; Papadimitriou JC; El-Hakim MS; El-Said AI; Ghannam BB; Silverberg SG
Arch Pathol Lab Med; 2001 Jul; 125(7):872-9. PubMed ID: 11419970
[TBL] [Abstract][Full Text] [Related]
12. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 1999 Sep; 74(3):385-94. PubMed ID: 10479498
[TBL] [Abstract][Full Text] [Related]
13. Proliferative activity in postmenopausal endometrium: the lurking potential for giving rise to an endometrial adenocarcinoma.
Sivridis E; Giatromanolaki A
J Clin Pathol; 2004 Aug; 57(8):840-4. PubMed ID: 15280405
[TBL] [Abstract][Full Text] [Related]
14. p53 staining as a prognostic indicator in endometrial carcinoma.
Ozsaran AA; Türker S; Dikmen Y; Erhan Y; Itil I; Terek C; Ozdemir N
Eur J Gynaecol Oncol; 1999; 20(2):156-9. PubMed ID: 10376438
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of Bcl-2, p53 overexpression, and lymph node metastasis in surgically staged endometrial carcinoma.
Ohkouchi T; Sakuragi N; Watari H; Nomura E; Todo Y; Yamada H; Fujimoto S
Am J Obstet Gynecol; 2002 Aug; 187(2):353-9. PubMed ID: 12193924
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical and in situ hybridization analysis of p53 in human endometrial carcinoma of the uterus.
Jiko K; Sasano H; Ito K; Ozawa N; Sato S; Yajima A
Anticancer Res; 1993; 13(2):305-10. PubMed ID: 8517643
[TBL] [Abstract][Full Text] [Related]
17. CD44 variant 6 in endometrioid carcinoma of the uterus: its expression in the adenocarcinoma component is an independent prognostic marker.
Hoshimoto K; Yamauchi N; Takazawa Y; Onda T; Taketani Y; Fukayama M
Pathol Res Pract; 2003; 199(2):71-7. PubMed ID: 12747468
[TBL] [Abstract][Full Text] [Related]
18. Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables.
Kyushima N; Watanabe J; Hata H; Jobo T; Kameya T; Kuramoto H
J Cancer Res Clin Oncol; 2002 Jun; 128(6):307-12. PubMed ID: 12073048
[TBL] [Abstract][Full Text] [Related]
19. [Status of fractionated abrasion and vaginal endocervical cytology in diagnosis of endometrial cancer].
Schild R; Kutta T
Geburtshilfe Frauenheilkd; 1992 Aug; 52(8):467-70. PubMed ID: 1397942
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical expression of cyclin E in endometrial adenocarcinoma (endometrioid type) and its clinicopathological significance.
Kato N; Watanabe J; Jobo T; Nishimura Y; Fujisawa T; Kamata Y; Kuramoto H
J Cancer Res Clin Oncol; 2003 Apr; 129(4):222-6. PubMed ID: 12684894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
